ReviewF1000Research2020
Recent advances in understanding and managing pediatric rhabdomyosarcoma.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rhabdomyosarcoma of the head and neck in pediatric patients: a systematic review.Medicina oral, patologia oral y cirugia bucal · 2022Pooled it
- Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group.Pediatric blood & cancer · 2024Trial
- Prognostic factors in pediatric head and neck rhabdomyosarcoma: a 30-year retrospective study in Brazil.Brazilian oral research · 2026Article
- Epigenetic paradigm of DNA methylation for understanding the pathophysiology, diagnostics, and therapeutics in sarcomas.Epigenomics · 2025Review
- Paediatric urachal rhabdomyosarcoma: the role of radiotherapy about a case report and review.Ecancermedicalscience · 2025Article
- HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.Cell death discovery · 2024Article
- Clinical outcomes and prognostic factors of parameningeal rhabdomyosarcoma in children and adolescents: results of two consecutive protocols.Translational pediatrics · 2024Article
- Review
- Case Report: Robotic pylorus-preserving pancreatoduodenectomy for periampullary rhabdomyosarcoma in a 3-year-old patient.Frontiers in surgery · 2024Article
- Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.Frontiers in oncology · 2024Article
- Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines.Journal of cancer research and clinical oncology · 2023Article
- Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group.Pediatric blood & cancer · 2023Article
- Staging Systems and Nomograms for Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Rhabdomyosarcoma in children: Retrospective analysis from a single tertiary care center in Saudi Arabia.Cancer reports (Hoboken, N.J.) · 2023Article
- About a Large Botryoid Rhabdomyosarcoma in a Little Girl: Management Difficulties and Literature Review.Case reports in obstetrics and gynecology · 2023Article
- An unusual presentation of neonatal rhabdomyosarcoma: a case report.Frontiers in pediatrics · 2023Article
- Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.JCO precision oncology · 2023Article
- Fisher discriminant model based on LASSO logistic regression for computed tomography imaging diagnosis of pelvic rhabdomyosarcoma in children.Scientific reports · 2022Article
- Urachal rhabdomyosarcoma: A case report of an extremely rare localisation.Urology case reports · 2022Article
- Prognostic factors of pediatric pelvic and genitourinary rhabdomyosarcoma: An analysis based on SEER database.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of >90%, 70%, and <30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.